Home Blog Page 170

Earth Mama brings on new vice-president

0
Earth Mama brings on new vice-president

Earth Mama® welcomes Guinevere C. Lynn as the vice-president of Sales. With over twenty years of sales experience and leadership, she brings a strategic approach along with a range of management talents applied to customer service, sales operations, strategic planning and innovative programs designed to serve the customer, the retailer and the distributor all at once. Guinevere will be responsible for all domestic sales for Earth Mama across all channels. Previous to joining Earth Mama, Guinevere applied her talents at some of the best companies in our industry, Gaia Herbs, Vega and for 15 years Sun Chlorella. She has been a material part of each of those industry leading company’s growth and success.

Founder and CEO Melinda Olson welcomes Guinevere’s innate understanding of natural brands and that she’s put Earth Mama products to use for her own childbirth experiences, “With her history and knowledge, we welcome her guidance as we expand our brand and presence. It’s a perfect fit, she’s a mama of three who knows a thing or two about both the wonders and indignities of pregnancy, childbirth, and postpartum and she knows the products firsthand.”

“Anyone who’s met Guin knows her glittering personality, but her knowledge and strategic sales leadership, consciousness of spirit and passionate love of all things Mama and Baby will help bring Earth Mama to another level, ensuring that every mother and every baby, through the world, will have efficacious plant based solutions,” says Papa in Charge Jagatjoti Singh Khalsa.

As for Lynn, she’s excited to be a part of the Earth Mama family, especially during this time of transition and growth, “It feels like such an exciting time to bring my strengths to Earth Mama, especially being a mama too!” She especially appreciates Natural Nipple Butter, “I lugged a breast pump across the nation for three kids and I swear the Natural Nipple Butter also helped with pumping nipple pain.”

Earth Mama Angel Baby manufactures trusted, certified organic, Non-GMO Project Verified and natural herbal products, gentle castile-based soaps, and teas that are specifically formulated to support the entire journey of childbirth, from pregnancy through postpartum recovery, breastfeeding, baby care, and even baby loss.

About Earth Mama®

For over a decade Earth Mama has offered trusted natural and organic herbal products for pregnancy, postpartum recovery, breastfeeding, baby care, and even the loss of a baby. Chosen by hospitals, Safe as Mama’s Arms®.

Earth Mama manufactures natural and organic herbal products that work, combining generations of women’s wisdom and traditional plant medicine with the safety and assurances of contemporary evidence based research. Certified by Oregon Tilth. To learn more, please visit http://www.earthmamaangelbaby.com.

ONFC signs letter of intent with Horizon Group

0
ONFC signs letter of intent with Horizon Group

The Ontario Federation of Food Co-operatives and Clubs, Inc., operating as the Ontario Natural Food Co-op, of Mississauga, has signed a Letter of Intent to sell its business and key assets to the Horizon Group of western Canada.

 

The co-operative’s board of directors invited ONFC members to a Special Members Meeting on Mar. 20 to consider the resolution that would allow the sale.

 

If the sale goes ahead, it would be an important step toward preserving a strong Canadian natural and organic food distribution system in the province, says ONFC General Manager Randy Whitteker. He notes that the roots of the Horizon Group are co-operative, and ONFC and Horizon Group share many values. Horizon Group’s Ontario operations would remain at the existing location in Mississauga, he adds.

 

He says that recent pressures in the organic and natural food industry, the co-operative’s expansion during this time, a strong U.S. dollar impacting the cost of imported products, and other reasons led to the boards’ decision to look to a bigger partner to maintain service for independent and other retail organic and natural retailers in Ontario.

 

Until a decision is made, the co-operative will continue to serve its members and customers which are buying clubs, local co-operatives, natural food retailers, restaurateurs, caterers and others dedicated to organic and natural food.

 

ONFC was founded in 1976. It now employs more than 120 people, and has close to 1500 members and customers. Its annual sales approach $55 million. ONFC owns Black River Juice Company Limited and the Ontario Natural Food Co-op brand. It distributes more than 4,500 grocery, refrigerated, frozen, bulk, and household items to natural and organic retailers in the eastern half of Canada. It is the 2016 Canadian Health Food Association Supplier of Excellence Award winner.

 

Also dating to 1976, the Horizon Group of companies is a key player in the natural products industry representing a wide array of categories shipped from a number of warehouses across Canada. Its subsidiary, Horizon Distributors, is western Canada’s leading distributor of organic and natural products in the dry, chill and frozen grocery categories, serving 1,800 locations annually including natural and organic retailers, grocery retailers, online retailers, buying clubs and major retail partners such as Whole Foods Market.

Canadian researchers join international fight against Zika 

0

The spread of the Zika virus, which can cause devastating birth defects, has become a pressing public health issue in many countries. To this day, there is no vaccine to prevent and no medicine to treat Zika virus infections.

The Honourable Jane Philpott, Canada’s Minister of Health, announced a $3 million investment for Zika research in May 2016. The Canadian Institutes of Health Research (CIHR), in partnership with the International Development Research Centre, today announced the names of the three teams of Canadian scientists who will collaborate with Latin American and Caribbean researchers to study the Zika virus.

The leaders of the three research teams include:

• Dr. Tom Hobman, from the University of Alberta. He and his team will study how the Zika virus changes host cells during infection, with the goal of developing anti-viral therapies that can be used against the virus.
• Dr. Keith Pardee, from the University of Toronto. He and his team will test a new, low-cost tool to rapidly detect the presence of Zika virus in patients’ bodily fluids. The new diagnostic tool is designed to be used in remote, under-resourced locations and will be field tested in Ecuador, Brazil and Colombia. Current tests to diagnose Zika virus are time consuming and prone to false positives due to the possibility of a patient’s prior infection with other flaviviruses such as dengue.
• Dr. Beate Sander, from Public Health Ontario. She and her team will conduct field studies in Argentina, Colombia and Ecuador to better understand how the virus is spread from mosquitoes to humans, predict which areas in the region are most at risk and use computer simulations to assess the most effective intervention methods, including mosquito control measures and vaccine development.

“The health research community is only beginning to come to grips with this dangerous pathogen. These three research teams have the potential to shed new light on the Zika virus and save lives,” says Dr. Marc Ouellette, the Scientific Director of the CIHR Institute of Infection and Immunity. “They may come up with faster ways to test for infection, finding the best methods to stop the mosquitoes that spread the virus and develop therapies that are effective against Zika.”

To date, there have been 481 cases of Zika virus detected in Canada, most of which have been travel related. However, the virus can also be transmitted from mother to fetus and sexually transmitted. There are currently no cures for Zika virus infections or vaccines available against the virus.

Additionally, Zika is linked to severe birth defects, like microcephaly. Moreover, it may cause neurological disorders including Guillain-Barré syndrome, a rare condition in which the body’s immune system attacks its nervous system. The Public Health Agency of Canada recommends that pregnant women and those planning a pregnancy avoid travel to countries or areas in the United States, like Florida, with reported mosquito-borne Zika virus.

Together, the international teams will create new knowledge to help develop diagnostics for Zika virus infection, understand the pathology caused by the virus, and ultimately prevent its transmission and morbidity.

Can probiotics prevent colic?

0

According to a new study, supplementing with probiotics during pregnancy and while breastfeeding may reduce colic in newborns.

The research, conducted by the University of Bari, looked at 66 pregnant women. Each subject was randomly given either a probiotic supplement or a placebo, starting at 36 weeks of their pregnancy and ending four weeks after birth.

After the study period, researchers observed an increase in cytokine levels in breast milk and secretory IgA in the women taking the probiotics. Both of the found molecules (IgA and cytokines) are key players in regulating immunity and inflammation. Researchers determined that probiotic maternal supplementation also helped to decrease instances of infantile colic and regurgitation in the babies. However, they did not find any evidence that this probiotic supplementation affected the composition of the newborns’ gut flora.

As such, taking a high-dose, multi-strain probiotic during pregnancy can help to improve gastrointestinal function in infants, aiding with colic. This will help to ensure that your clients’ journey into motherhood is a smooth one, giving extra comfort to newborns.

Vitamin B3 relieves peripheral neuropathy in breast/ovarian cancer patients

0

Researchers from the University of Iowa have discovered that a novel form of viamin B3, known as NIAGEN® Nicotinamide Riboside (NR), may be effective in relieving chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.

Published in the Journal of the International Association for the Study of Pain (PAIN), the study showed that NR ameliorates CIPN in an animal model.
 
Currently, the American Society for Clinical Oncology considers the development of adjunctive therapy for the prevention and relief of CIPN as essential for patient care. This study provides an important proof of concept for the use of NR as a novel therapeutic approach in filling the unmet need for treatments that alleviate CIPN.
  
Led by Dr. Donna Hammond, Ph.D., the research team at the University of Iowa demonstrated that treatment with NR increased blood levels of nicotinamide adenine dinucleotide (NAD+) by 50 per cent after three weeks of daily administration. NR was able to prevent the development of tactile hypersensitivity induced by the chemotherapeutic paclitaxel and reverse well-established tactile hypersensitivity, while also blunting escape/avoidance behaviors. Furthermore, the prophylactic effect was sustained for at least two weeks after treatment with NR ceased.
 
Dr. Marta Hamity, Ph.D., the lead study author, indicated that the team embarked on the study based on evidence that suggested that increasing levels of NAD+ in the cells may protect against neuronal injury. The study used female Sprague-Dawley rats, clinically relevant doses of paclitaxel and incorporated measures that quantify the impact of CIPN on quality of life.
 
“This is significant because the pain associated with CIPN can increase as the [chemotherapy] dose escalates, and at times it reaches a point where the patient is no longer able to tolerate the effective doses,” explained Hammond. “The American Society of Clinical Oncology has issued a position paper that there is an unmet need for treatments that can alleviate CIPN. This study has provided positive data which is particularly exciting considering the unmet need for therapies in this area. We believe that further development of NR as a therapy for CIPN is warranted.” 
NIAGEN®, a product created by ChromaDex, is the only commercially available form of NR. For additional information about ChromaDex and NIAGEN®, visit www.Chromadex.com.

Government of Canada invests in dementia research about Indigenous Peoples

0

Paul Lefebvre, Member of Parliament for Sudbury, on behalf of the Honourable Jane Philpott, Minister of Health, has announced an investment of $1 million for two research projects that will bring new and culturally-adapted approaches to address the needs of Indigenous peoples living with or at risk of developing dementia.

The new investment from the Canadian Institutes of Health Research (CIHR) will fund the work of top researchers at the Health Sciences North Research Institute and Laurentian University in Sudbury. 
 
– Dr. Janet McElhaney received $500,000 to use a community-based approach that will combine Indigenous practices with Western technologies to empower caregivers supporting older Indigenous peoples with dementia.

– Dr. Jennifer Walker received $500,000 to develop a Canadian Indigenous Cognitive Assessment Tool for widespread use and to lay a foundation for a national study of dementia in Indigenous populations. 

“Investing in projects aimed at advancing our understanding of Indigenous Peoples’ health is a priority for CIHR,” says Dr. Carrie Bourassa, Scientific Director at the CIHR Institute of Aboriginal Peoples’ Health. “I’m confident that the grant recipients will develop culturally appropriate diagnostic tools and care models for both rural and urban Indigenous peoples. New data will help target the best health care services.”

These projects are part of the CIHR Dementia Research Strategy, which supports research on the latest preventive, diagnostic and treatment approaches to Alzheimer’s disease and related dementia.

MusclePharm launches allergen-free, vegan line

0
MusclePharm launches allergen-free

MusclePharm, a scientifically-driven, performance lifestyle sports nutrition company, has launched its Natural Series. This line of plant-based, vegan, gluten-free, soy-free, non-GMO, premium products targets individuals seeking an organic alternative to traditional nutritional products and supplements.

 

The new line launched at Natural Products Expo West, the world’s largest natural products event. These products complement MusclePharm’s existing range of premium-quality products, and represents a new retail category for the company, which made its name as a leader in the sports nutrition industry.

 

“Natural Series represents both a logical extension and a tremendous opportunity for MusclePharm to capitalize on the brand recognition and consumer acceptance of our products,” says Ryan Drexler, CEO and chairman of the board for MusclePharm. “In addition, the launch underscores our commitment to providing our customers with high-quality products that support their diverse fitness needs and goals.”

 

Adds Drexler, “From professional athletes to weekend warriors, we strive to cater to every subset of the active population and offer scientifically-proven products that optimize results. We are expanding our line in response to the burgeoning demand for nutritious, all-natural organic offerings that promote healthy lifestyles and environmental sustainability.”

 

Select items in the Natural Series are certified USDA Organic, denoting third-party verification of their quality and purity, and demonstrating best practices and careful stewardship. These include:

 

  • MusclePharm USDA Organic Plant-Based Performance Protein – a blend of raw, all-organic protein sourced from Pea Protein isolate, and QuinoaTrim™ Quinoa – delivering all essential amino acids to support daily nutrition and performance.
  • MusclePharm USDA Organic Superfoods – a combination of organic greens, fruits and vegetables, ancient grains, and sprouted whole foods that serve any active lifestyle. To maximize these superfoods’ power, aloe vera, a full spectrum of digestive enzymes, and probiotics, help promote superior digestion and bioavailability.
  • MusclePharm Organic Protein Bars – featuring complete proteins sourced from organic whole-grain brown rice protein, and organic pea protein, to provide all the beneficial lean muscle-building benefits of protein through an all-natural, organic, and great-tasting small meal alternative.
  • MusclePharm Pre-Workout – a combination of caffeine, natural botanicals, electrolytes, and Amino Acids that work together to support training goals and provide pure, unadulterated results, naturally.

 

According to Zion Market Research, the global dietary supplements market continues to expand and is expected to reach $220.3 billion in 2022, while the Organic Trade Association (OTA) notes that the organic industry is also experiencing unprecedented growth, up 11 percent (for a total of $43.3 billion) in 2015.

 

“Both the all-natural and organic segments represent the fastest-growing corner of the market, and MusclePharm is a brand uniquely positioned to capitalize on this opportunity,” adds Drexler. “Over the past year, we have worked closely with regulatory bodies to secure USDA Organic certification for a majority of these products, which not only differentiates the Natural Series from its competitors, but effectively positions MusclePharm to further penetrate its existing distribution channels and enter new markets.”

 

About MusclePharm Corporation

 

MusclePharm® is a scientifically-driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. Its portfolio of recognized brands includes MusclePharm® Sport Series, Black Label and Core Series, and FitMiss™, which are available in more than 120 countries and over 50,000 retail outlets worldwide. The clinically-proven supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit http://www.musclepharm.com. To sign up to receive MusclePharm news via email, please visit http://ir.musclepharmcorp.com/email-alerts.

Could probiotics be the next trend in the aging market?

0

According to a new systematic review, probiotics may enhance cellular immune activity in healthy elderly adults.
Four clinical trials were included in this analysis. Data showed that B. lactis HN019™, a product from DuPont Nutrition and Health’s Danisco® range, was highly efficacious in increasing polymorphonuclear (PMN) phagocytic capacity and natural killer (NK) cell tumoricidal activity.
“This is the first Systematic Review and meta-analysis of the probiotic strain Bifidobacterium animalis ssp. lactis HN019™ in relation to immune function in elderly – a highly relevant target group since elderly people have increased susceptibility to infections and cancer that are associated with decline in cellular immune function,” said Liisa Lehtoranta, research manager, DuPont Nutrition & Health.
Elderly people represent the fastest growing population globally. Typically, the elderly population has weaker immune responses to vaccination and elevated risk for infections, certain autoimmune diseases, and cancer. Several of these health risks are a consequence of weakening immune function associated with the aging process, also known as immunosenescence. Gut microbiota plays a significant role in immunosenescence, and is influenced by physiological aging process, lifestyle, and diet.
Research shows that gut microbiota of the elderly has specific features compared to microbiota of younger adults, such as lower levels of bifidobacteria and higher levels of Bacteroidetes spp. These changes in microbiota composition may be indicative of dysbiosis and poorer health. As such, targeted dietary interventions which restore microbiota composition could potentially help maintain overall health and improve the quality of the life of the elderly.

Cross-border e-commerce more susceptible to fraud

0
Cross-border e-commerce more susceptible to fraud

According to data by Radial, cross-border ecommerce is proven to be much more susceptible to fraud than domestic ecommerce. The data, which covers over 100 clients in eight different verticals and over 100 million transactions, showed that cross-order ecommerce was riskier. LexisNexis data confirms that international online/mobile channels suffer 2.5 times more successful fraud than domestic-only remote channels.

 

Cleveland Brown, CEO of leading global payment processing provider Payscout, Inc., said these findings underscore the importance of risk analysis and fraud management for global ecommerce merchants.

 

According to Business Insider, U.S. retailers lost roughly $32 billion to fraud in 2014—a 39 per cent increase over the $23 billion in fraud losses the prior year. LexisNexis reports that international merchants with ecommerce/mcommerce transactions have the highest fraud costs as a percentage of annual revenues; their costs are nearly 22 per cent higher than the average multi-channel merchant, and 85 per cent higher than international merchants that operate physical stores only.

 

“While fraud remains an ongoing challenge for all retailers, these findings suggest that cross-border merchants should be particularly diligent in their efforts to combat fraud—both to prevent financial losses and to reassure consumers their data is secure,” said Brown. “This means addressing fraud on multiple fronts and using layered solutions.”

 

International merchants contend with several types of fraud; those with e/mcommerce channels attributed 30 per cent of their losses to friendly fraud, 30 per cent to lost or stolen merchandise, 22 per cent to identity theft and 17 per cent to fraudulent requests for return/refund.

 

Retailers also have to protect their customers’ information from cyber-attacks and data breaches, and they need to avoid declining legitimate transactions on suspicion of fraud. Among large cross-border merchants, 31 per cent of declined transactions turned out to be false positives.

 

The good news is that multi-layered fraud solutions have the potential to reduce false positives from roughly 1 in 3 to 1 in 5, and to cut the average monthly number of successful fraud attempts by more than half. Brown notes that international merchants can mitigate their fraud risk by starting with a secure payment system and building on that foundation with comprehensive online fraud protection. By providing global payment solutions for merchants in all risk verticals, Payscout has built a best-in-class suite of fraud protection tools that can support any global entrepreneur.

 

“Effective fraud management is every bit as important to a web-based business’ success as transaction and payment processing,” Brown explained. “That’s why in addition to providing ecommerce merchants with a robust, flexible and secure payment infrastructure, Payscout assists them with advanced fraud protection solutions.”

 

Payscout’s managed risk analysts support thousands of clients on six continents with a range of proven tools and strategies, from automated fraud screening and manual reviews to risk management assessments and performance audits. “We maintain a global knowledge network that helps identify new fraud trends before they impact our clients’ businesses, ultimately enabling ecommerce merchants to accept more good orders and reduce their risk of fraud,” concluded Brown.

Could immunotherapy cure brain cancer?

0

A promising combination of immunotherapies delivers a one-two punch to brain cancer tumours with high cure rates in mice, scientific evidence published in Nature Communications says.

Researchers at the Children’s Hospital of Eastern Ontario (CHEO) in Ottawa found that a combination of drugs known as SMAC Mimetics and immune checkpoint inhibitors (ICIs) amplifies kill rates of cancer tumour cells in laboratory testing. Researchers also discovered a new mechanism by which the combination promotes long-term immunity against glioblastoma tumours. The combination therapy also proved to be highly effective against breast cancer and multiple myeloma.

“These findings represent a significant evolution in our research and the field of immunotherapy. We are the first in the world to show the synergistic tumour-killing impact of combining SMAC Mimetics with immune checkpoint inhibitors for glioblastoma,” said Dr. Robert Korneluk, distinguished professor at the University of Ottawa and senior scientist at the CHEO Research Institute. “You could say it takes two to tango. We believe that it takes a combination strategy to impact cancer cure rates.”

In 2014, a team of scientists led by Dr. Korneluk discovered that combining SMAC Mimetics with immune stimulators or live virus therapies had a synergistic or amplified tumour-killing effect that was greater than either agent on its own. Today’s news shows that SMAC Mimetics also have a powerful synergistic effect with ICIs, relatively new drugs that are showing great promise in the clinic. SMAC Mimetics known as LCL161 and Birinapant were combined with ICI antibodies targeting PD-1 and CTLA-4 immune checkpoints.

Eric Lacasse, a scientist at the CHEO Research Institute, said: “Two drug companies have initiated human clinical trials this year to assess the impact of this combination of SMAC Mimetics and ICIs on patients with a variety of cancers. Although it could be years before any clinical trials begin for adults or children with the deadly brain cancer, glioblastoma, we’re looking forward to seeing how scientific evidence from these experimental treatments adds to our knowledge. It’s an exciting, exploratory field and we hope we’ve hit a home run.”

Shawn Beug, lead author of the 2014 and 2017 papers, said: “This research heightens our understanding of the mechanics behind this double-whammy effect, which both enhances the immune response and weakens tumour cells to immune attack. We’re hoping that more oncologists and biotech companies test out this combination in clinical trials as we continue to decipher how SMAC Mimetics encourage the immune system to kill cancer cells.”

The research was funded by the Canadian Cancer Society Research Institute, Brain Canada (with financial support from Health Canada through the Canada Brain Research Fund) and the Canadian Institutes of Health Research. In addition, the work was supported by donations to the Ottawa Regional Cancer Foundation, the Kiwanis Medical Foundation and the CHEO Foundation.

The University of Ottawa—A crossroads of cultures and ideas
The University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada’s top 10 research universities—our professors and researchers explore new approaches to today’s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe.

About the CHEO Research Institute
The CHEO Research Institute coordinates the research activities of the Children’s Hospital of Eastern Ontario (CHEO) and is affiliated with the University of Ottawa. Its three programs of research include molecular biomedicine, health information technology, and evidence to practice research. Key themes include cancer, diabetes, obesity, mental health, emergency medicine, musculoskeletal health, electronic health information and privacy, and genetics of rare disease. The CHEO Research Institute makes discoveries today for healthier kids tomorrow. For more information, visit www.cheori.org.